New psoriasis drug goes head-to-head with cosentyx in major trial
NCT ID NCT06630559
First seen Feb 25, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This study tests a new medicine called CT-P55 against the approved drug Cosentyx in 153 adults with moderate to severe plaque psoriasis. The goal is to see if CT-P55 works as well and is as safe. Participants must have had psoriasis for at least 6 months and cannot have used certain similar drugs before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rheumatology Clinic NZOZ Lecznica MAK-MED s.c.
Nadarzyn, Poland
Conditions
Explore the condition pages connected to this study.